Latest Keith Flaherty Stories
Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared.
Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.